Synthetics Biologics, Inc., a biotechnology company, focuses on the development of biologics for the prevention and treatment of serious infectious diseases. The company's product candidates include Trimesta, which is in Phase II clinical trial for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-004, which is in Phase II clinical trial for the treatment of clostridium difficile infection prevention; SYN-005, which is in preclinical stage for the treatment of pertussis; and SYN-001, which is in discovery stage for the treatment of acinetobacter infection. It has an agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan, as well as with The University of Texas at Austin, Intrexon Corporation, and the Regents of the University of California. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.
Address
Suite 412, 4th Floor, 155 Gibbs Street
ROCKVILLE, MD 20850
United States
ROCKVILLE, MD 20850
United States
Key stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -162.96% | -165.41% |
| Return on average equity | -171.36% | -172.09% |
| Employees | 8 |
No comments:
Post a Comment